Browsing by Author "Wang, Jian"

Now showing 1 - 8 of 8
  • Thumbnail Image
    ItemOpen Access
    Comparing public and private hospitals in China: Evidence from Guangdong
    (BioMed Central, 2010-03-23) Eggleston, Karen; Lu, Mingshan; Li, Congdong; Wang, Jian; Yang, Zhe; Zhang, Jing; Quan, Hude
  • Thumbnail Image
    ItemOpen Access
    Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China
    (BioMed Central, 2013-01-31) Lu, Jingjing; Xu, Aiqiang; Wang, Jian; Zhang, Li; Song, Lizhi; Li, Renpeng; Zhang, Shunxiang; Zhuang, Guihua; Lu, Mingshan
  • Thumbnail Image
    ItemOpen Access
    Does the new cooperative medical scheme reduce inequality in catastrophic health expenditure in rural China?
    (2016-11-14) Guo, Na; Iversen, Tor; Lu, Mingshan; Wang, Jian; Shi, Luwen
    Abstract Background In 2003, the New Cooperative Medical Scheme (NCMS) was introduced in China to re-establish health insurance for the country’s vast rural population. In addition, the coverage of NCMS has been expanding after the new health care reform launched in 2009. This study aims to examine whether the NCMS and its recent expansion have reached the goal of reducing the risk and inequality of catastrophic health spending for rural residents in China. Methods We conducted a face-to-face household survey in three counties of the Shandong province in 2009 and 2012. Using this unique panel data, we examined the changes in the incidence and intensity of catastrophic health expenditures (CHEs) before and after NCMS reimbursement. We used concentration index (CI) and decomposition method to study the changes in inequality in CHEs. Results We found that NCMS reimbursement played a role of reducing both the incidence and intensity of CHEs, and that this impact was stronger after the new health care reform was launched. After reimbursement, the concentration indices for CHEs were 0.073 and 0.021 in 2009 and 2012, indicating that the rich had a greater tendency to incur CHEs and there existed less inequality in the incidence of CHEs after reimbursement in 2012 compared with 2009. The decomposition analysis results suggested that changes in CHE inequality between 2009 and 2012 were attributed to changes in economic status and household size rather than reimbursement levels. Conclusions Our results indicated that inequality was shrinking from 2009 to 2012, which could be a result of fewer rich people having CHEs in 2012 compared with 2009. The impact of NCMS in alleviating the financial burden of rural residents was still limited, especially among the poor. Health care reform policies in China that aim to reduce CHEs must continue to place an emphasis on improving reimbursement, cost containment, and reducing income inequalities.
  • Thumbnail Image
    ItemOpen Access
    Gap Analysis of Public Mental Health and Addictions Programs (GAP-MAP) Final Report
    (Government of Alberta, 2014-02) Wild, T. Cameron; Wolfe, Jody; Wang, Jian; Ohinmaa, Arto
    Results from the project are intended to lay the groundwork for building a population-based model for addiction and mental health service planning in Alberta. Although many of the project’s conclusions echo longstanding concerns expressed by stakeholders about Alberta’s system of care for addiction and mental health problems, GAP-MAP went beyond anecdotal observations to collect systematic empirical data on unmet population need, service capacity, and costs. In addition to providing a relatively fine-grained description of these topics, the project synthesized findings from these data sources to provide examples of how needs-based planning for addiction and mental health services could be undertaken.
  • Thumbnail Image
    ItemOpen Access
    Growing old before growing rich: inequality in health service utilization among the mid-aged and elderly in Gansu and Zhejiang Provinces, China
    (BioMed Central, 2012-09-04) Wang, Yang; Wang, Jian; Maitland, Elizabeth; Zhao, Yaohui; Nicholas, Stephen; Lu, Mingshan
  • Thumbnail Image
    ItemOpen Access
    Ndel1 promotes axon regeneration via intermediate filaments
    (Public Library of Science, 2008-04-23) Toth, Cory; Shim, Su Yeon; Wang, Jian; Jiang, Yulan; Neumayer, Gernot; Belzil, Camille; Liu, Wei-Qiao; Martinez, Jose; Zochodne, Douglas; Nguyen, Minh Dang
  • Thumbnail Image
    ItemOpen Access
    Polarizable point-charge model for water: Results under normal and extreme conditions
    (American Institute of Physics, 1996) Kusalik, Peter G.; Svishchev, Igor M.; Wang, Jian; Boyd, Russel J.
  • Thumbnail Image
    ItemOpen Access
    Targeted next generation sequencing as a tool for precision medicine
    (2019-06-03) Gulilat, Markus; Lamb, Tyler; Teft, Wendy A; Wang, Jian; Dron, Jacqueline S; Robinson, John F; Tirona, Rommel G; Hegele, Robert A; Kim, Richard B; Schwarz, Ute I
    Abstract Background Targeted next-generation sequencing (NGS) enables rapid identification of common and rare genetic variation. The detection of variants contributing to therapeutic drug response or adverse effects is essential for implementation of individualized pharmacotherapy. Successful application of short-read based NGS to pharmacogenes with high sequence homology, nearby pseudogenes and complex structure has been previously shown despite anticipated technical challenges. However, little is known regarding the utility of such panels to detect copy number variation (CNV) in the highly polymorphic cytochrome P450 (CYP) 2D6 gene, or to identify the promoter (TA)7 TAA repeat polymorphism UDP glucuronosyltransferase (UGT) 1A1*28. Here we developed and validated PGxSeq, a targeted exome panel for pharmacogenes pertinent to drug disposition and/or response. Methods A panel of capture probes was generated to assess 422 kb of total coding region in 100 pharmacogenes. NGS was carried out in 235 subjects, and sequencing performance and accuracy of variant discovery validated in clinically relevant pharmacogenes. CYP2D6 CNV was determined using the bioinformatics tool CNV caller (VarSeq). Identified SNVs were assessed in terms of population allele frequency and predicted functional effects through in silico algorithms. Results Adequate performance of the PGxSeq panel was demonstrated with a depth-of-coverage (DOC) ≥ 20× for at least 94% of the target sequence. We showed accurate detection of 39 clinically relevant gene variants compared to standard genotyping techniques (99.9% concordance), including CYP2D6 CNV and UGT1A1*28. Allele frequency of rare or novel variants and predicted function in 235 subjects mirrored findings from large genomic datasets. A large proportion of patients (78%, 183 out of 235) were identified as homozygous carriers of at least one variant necessitating altered pharmacotherapy. Conclusions PGxSeq can serve as a comprehensive, rapid, and reliable approach for the detection of common and novel SNVs in pharmacogenes benefiting the emerging field of precision medicine.